Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI

Sazan Rasul,1 Barbara Katharina Geist,1 Helmut Brath,2 Pascal Baltzer,3 Lalith Kumar Shiyam Sundar,4 Verena Pichler,1 Markus Mitterhauser,5 Alexandra Kautzky-Willer,6 Marcus Hacker1

ABSTRACT

Introduction Inhibitors of sodium-glucose linked transporter-2 (SGLT2) are enhancing glucose excretion in the proximal renal tubules, and thus are increasingly used to lower blood glucose levels in patients with type 2 diabetes mellitus (T2DM). The glucose analog 2-deoxy-2-(18F) fluoro-D-glucose (FDG) can be used to quantify renal function in vivo, and due to an affinity for SGLT2 could also provide information about SGLT2 transporter function. Our objectives in this study were, therefore, to assess the impact of SGLT2 on renal function parameters in patients with T2DM and identify predictive parameters of long-term response to SGLT2 using dynamic FDG positron emission tomography (PET)/MRI.

Methods PET FDG renal function measures such as mean transit time (MTT) and general renal performance (GRP) together with glomerular filtration rate (GFR) were determined in 20 patients with T2DM before (T2DMbaseline) and 2 weeks after initiation of therapy with SGLT2i (T2DMSGLT2i). Additionally, dynamic FDG PET data of 24 healthy subjects were used as controls.

Results MTT in T2DMbaseline was significantly higher than in healthy controls (5.7 min vs 4.3 min, p=0.012) and significantly decreased to 4.4 min in T2DMSGLT2i (p=0.004). GRP of T2DMSGLT2i was higher than T2DMbaseline (5.2 vs 4.7, p=0.02) and higher but not significantly than of healthy individuals (5.2 vs 5.1, p=0.34). Expectedly, GFR of healthy participants was significantly higher than of T2DMbaseline and T2DMSGLT2i (122 vs 92 and 86 mL/min/1.73 m², respectively; p<0.001). The higher the GRP value in kidneys of T2DMSGLT2i, the lower was the glycated hemoglobin level 3 months after therapy initiation.

Conclusion MTT and GRP values of patients with T2DM shifted significantly toward values of healthy control 2 weeks after therapy with SGLT2i begins. GRP in T2DMSGLT2i was associated with better long-term glycemic response 3 months after initiation of therapy.

Trial registration number NCT03557138.

INTRODUCTION

Glucose transporters (GLUTs) and sodium-dependent glucose cotransporters, also known as sodium-glucose linked transporters (SGLTs), are mediators for glucose transportation and play prominent roles in cellular glucose uptake, homeostasis and metabolism. While GLUTs mediate the glucose uptake in the brain, heart and liver, SGLTs are primarily responsible for glucose transport in the kidney.1 Inhibition of the protein SGLT2 is the key mechanism of action of gliflozin drugs that are used as oral antidiabetic therapy in patients with type 2 diabetes mellitus (T2DM), the most common type of diabetes.

SGLT2s are mainly expressed in the proximal tubule segments of the nephron and are responsible for the reabsorption of more than 90% of the filtered glucose that normally takes place in glomerular capillary membranes.5 Expression of SGLT2 proteins in renal proximal tubules is positively correlated with the levels of blood glucose and is significantly higher in patients with diabetes than in healthy individuals.7 Via hindrance of glucose
reabsorption, SGLT2 inhibitors (SGLT2i) increase the rate of glucose excretion in the proximal renal tubules and subsequently induce glucosuria and reduce blood glucose level. Aside from the fact that the therapy might be associated with some adverse effects such as urinary tract infection, pollakisuria or ketoacidosis, numerous studies could demonstrate improvement of insulin resistance and glycemic control with reduction of glycated hemoglobin (HbA1c) levels, body weight and blood pressure values in patients with T2DM treated with SGLT2i.4-8 Furthermore, according to observations of previous studies, SGLT2i, additionally, can safely be applied to patients with diabetes having mild to moderate chronic kidney diseases9 and offer renoprotective effects such as improvement of glomerular filtration rate (GFR) and albuminuria for these patients.10 11

The glucose analog 2-deoxy-2-(18F) fluoro-D-glucose (FDG) is the most frequently routinely used radiopharmaceutical for positron emission tomography (PET), particularly to detect tumorous cells and inflammatory tissues. Indeed, FDG reaches organs via different GLUTs, whereby GLUT-2 is responsible for the glucose uptake in the kidneys.1 Although several reports from previous studies revealed no reabsorption of FDG in the proximal tubules of the kidney,12 13 some experimental studies demonstrated slight SGLT2 affinity for FDG and showed that under normal conditions about 10% of FDG was reabsorbed in the proximal tubule.14 A major fraction of the tracer, however, is excreted via glomerular filtration through the kidneys, which enables the reliable estimation of various renal functional parameters including GFR and outflow efficiency.15 Based on these observations, we conducted a prospective clinical trial to analyze the effects of SGLT2i treatment on both renal function and glucose utilization in patients with T2DM and healthy individuals using dynamic FDG PET/MRI scans. One of the renal function parameters that are frequently used in nuclear medicine is the mean transit time (MTT), which is the averaged travel time of a tracer through a certain tissue and is used to quantify absolute renal function as well as renal outflow.16 Furthermore, the renal tracer uptake within the first minutes of tracer injection is used to quantify the general renal performance (GRP), a parameter that is generally used to determine differential renal function or GFR.17 We hypothesized that FDG renal parameters such as MTT, outflow efficacy and GRP measured at baseline (T2DM_baseline) and 2 weeks after initiation of gliflozin therapy (T2DM_sGLT2i) could be used to indicate a patient’s response 3 months after initiation of SGLT2i therapy.

**STUDY DESIGN AND METHODS**

**Patients**

Twenty consecutive patients with T2DM (10 men and 10 women, aged 65±10 years (range 38–78)) with a mean HbA1c of 7.5% (58 mmol/mol)±0.9 (range 6.6 (49)–9.8 (84)) and a mean interval from first diagnosis of diabetes of 12 years (range 1–30) were included in this prospective clinical trial. All patients underwent two dynamic FDG PET/MRI examinations: one before and the other 2 weeks after initiation of SGLT2i therapies.

A written informed consent was provided by every studied patient prior to study participation. Inclusion criteria were T2DM, age between 20 and 74 years, HbA1c level >6.2%, planned initiation with SGLT2i treatment and intact renal function (serum creatinine <1.5 mg/dL or urinary albumin to creatinine ratio <300 mg/g in a random urine sample). Exclusion criteria were anatomically altered or harmed kidneys, corticosteroids and diuretic therapies, MRI unsafe implants such as pacemakers and implantable cardioverter-defibrillators, previously not tolerated MRI contrast agents, claustrophobia, not able to lie still without changing position for a minimum of 30 min, and pregnancy.

Twenty-four healthy individuals (18 men, 6 women), with a mean age of 39±9 (range 21–65 years), scanned with the same FDG PET/MRI protocol, served as a control group.

**SGLT2i therapy and follow-up**

The clinical indication for SGLT2i therapies was independent of the onset of T2DM and was recommended by experienced diabetologists based on the current international guidelines18 as monotherapy or in combination with other antidiabetic medications, including insulin the day after the baseline PET/MRI scan. Of the 20 patients, 16 (80%) were treated with 10 mg daily dose of empagliflozin (Jardiance) and 4 patients with 10 mg daily dose of dapagliflozin (Forxiga).

Therapy response was documented 3 months after initiation of SGLT2i therapy by determination of HbA1c serum levels. According to the reduction of HbA1c level in relation to baseline, we divided patients into two groups: responder with any reduction of the original HbA1c value and non-responder with no change or increase of HbA1c.

**FDG positron emission tomography/MRI**

After obtaining fasting blood samples to determine metabolic and chemical laboratory parameters (blood lipids, renal and kidney functions) and after an intravenous hydration with 500 mL 0.9% NaCl (normal saline), participants were asked to empty their bladder directly before injection of 3 MBq/kg body weight of 18F-FDG. PET acquisition (Siemens Biograph mMR, Siemens Healthcare Diagnostics, Germany) started immediately after tracer injection and continued for 30 min. The field of view covered the abdomen, including the kidneys and the abdominal aorta. PET list-mode data were reconstructed into a dynamic sequence, 60×5 s, 25×60 s, and each PET frame was reconstructed (Siemens e7 tools) into a 172×172×127 matrix using the ordinary Poisson ordered subset expectation maximization three-dimensional algorithm (3 iterations, 21 subsets, Gaussian filter). Scatter correction was performed with Dixon-based magnetic resonance-attenuation correction.
Simultaneously acquired MRI consisted of a T1-weighted sequence with axial breath holding, fat suppression and spectrally adiabatic inversion recovery (VIBE SPAIR) and was used to accurately delineate kidneys and vessels.

For PET/MRI analysis, three volumes-of-interest (VOIs) were manually drawn in respective layers of the T1 MRI sequence using the Hermes Hybrid Viewer (Hermes Medical Solutions, Stockholm, Sweden): (1) descending aorta between the diaphragm and the renal arteries, (2) left kidney, and (3) right kidney. After delineation, the VOIs were copied to the PET images, from which the FDG time activity curves (TACs) were calculated in units of kBq/mL.

FDG TAC analysis was performed using an inhouse Java-based tool (programmed with OpenJDK V1.8.0_162). The program was fed with the TACs of the kidneys as well as the aorta, which was also used as arterial input function (AIF). The mean of standardized uptake value (SUV) uptake between 2 and 3 min was additionally determined for each kidney by calculating the integral of the sum of the according TAC between 2 and 3 min after FDG injection. This cumulative uptake was considered as a measure for GRP and was previously used for determination of various kidney parameters.16-21

For the MTT that represents kidney excretion rate, the renal retention function of a corresponding TAC needed to be determined.22 The retention function was calculated from the AIF with a matrix deconvolution algorithm according to Kempi.23 In order to reduce noise and to smooth the curves, a Savitzky-Golay filter was applied on the TACs before deconvolution.24 The MTT was then calculated for each kidney by dividing the area under retention function by the height of the plateau.25

Statistical analysis
Statistical analysis was performed using Gnumeric (open-source software, V.1.12.20), LibreOffice Calculator (open-source software, V.6.0.3.2) and SPSS V.24.0. Kolmogorov-Smirnov test was used to determine distribution of the studied parameters. Not normally distributed data are presented as medians and ranges and were log10-transformed for all statistical analyses. Correlations have been calculated with Pearson product-moment correlation coefficient r, from which p values were derived. The significance of differences between values was determined with a paired Student’s t-test, where p<0.05 was considered a statistically significant difference.

RESULTS
The demographical parameters of the healthy participants and of the 20 patients with T2DM (10 men, 10 women) at baseline are shown in table 1. In addition, clinical and laboratory parameters measured at baseline and 2 weeks after SGLT2i therapy are presented in table 2.

### Table 1
Demographics of the 20 studied patients with type 2 diabetes mellitus before starting SGLT2i therapies and the 24 healthy participants

| Parameters                        | Patients with type 2 diabetes (n=20) | Healthy control (n=24) |
|-----------------------------------|-------------------------------------|------------------------|
| Gender (%)                        | 50% male, 50% female                | 75% male, 25% female   |
| Age (years), mean±SD              | 65±10 (range 39–78)                 | 39±9 (range 21–65)     |
| Weight (kg), mean±SD              | 87±16                               | 85±18                  |
| BMI (kg/m²), mean±SD              | 31±5                                | 26±5                   |
| Baseline HbA1c, % (mmol/mol), mean±SD| 7.5 (58)±0.9, range 6.6–(49–9.8)  | n.a.                   |
| Duration of diabetes (years), mean±SD| 12±8 (range 1–30)                 | n.a.                   |
| Concomitant antidiabetic medication, n (%) | n.a.                          |                        |
| Only insulin                      | 3 (15)                              |                        |
| Insulin + OADs                     | 1 (5)                               |                        |
| Only OADs                         | 13 (65)                             |                        |
| No previous therapies             | 3 (15)                              |                        |
| Cardiovascular diseases, n (%)    | n.a.                                |                        |
| CHD                               | 4 (20)                              |                        |
| HTN                               | 18 (90)                             |                        |
| On RAAS inhibitors                | 12 (60)                             |                        |
| No RAAS inhibitors                | 8 (40)                              |                        |
| Hyperlipidemia, n (%)             | 19 (95)                             |                        |
| Smoking status, n (%)             | n.a.                                |                        |
| Never                             | 9 (45)                              | 13 (54.2)              |
| Former                            | 8 (40)                              | 4 (16.6)               |
| Current                           | 3 (15)                              | 7 (29.2)               |

BMI, body mass index; CHD, coronary artery disease; HbA1c, glycated hemoglobin; HTN, arterial hypertension; n.a., not applicable; OADs, oral antidiabetic drugs; RAAS, renin-angiotensin-aldosterone system inhibitors; SGLT2i, sodium-glucose linked transporter-2 inhibitor.

GFR values at T2DMbaseline and T2DMSGLT2i were significantly lower as compared with healthy controls (92 and 86 vs 122 mL/min/1.73 m², respectively, both p<0.001; table 3). The MTT in patients with T2DM at baseline was significantly higher than in healthy controls (5.7 min vs 4.3 min, p=0.012), but significantly decreased from 5.7 min at baseline to 4.4 min after 2 weeks of therapy (p=0.004; figure 1A, table 3).

Similarly, the GRP in patients with T2DM at baseline was markedly lower when compared with healthy individuals (4.7 min vs 5.1 min), but did not reach statistical significance (p=0.06). Two weeks after SGLT2i treatment, GRP significantly increased from 4.7 to 5.2 (p=0.02) to a similar range as in healthy controls (5.1 min) (figure 1B, table 2).

### Table 2
Change of renal parameters under SGLT2i therapy

While both GFR and creatinine levels of patients with T2DM showed no significant change during therapy,...
Emerging Technologies, Pharmacology and Therapeutics

Table 2  Clinical and laboratory parameters of the 20 patients with type 2 diabetes (10 male, 10 female), measured at baseline and 2 weeks after receiving SGLT2i therapies

| Parameters (mean±SD) | T2DM baseline | T2DM SGLT2i | P value |
|----------------------|--------------|-------------|---------|
| Weight (kg)          | 87.45±16     | 87.25±16    | NS      |
| Blood pressure (mm Hg) |            |             |         |
| Systolic             | 134±12       | 131±13      | NS      |
| Diastolic             | 77±11        | 77±9        | NS      |
| HbA1c, % (mmol/mol)* | 7.45 (58)±0.87 | 6.95 (52)±0.63 | 0.006 |
| Glucose (mg/dL)      | 158±43       | 138±34      | 0.01    |
| Hematocrit (%)       | 41.6±2.8     | 41.7±3.1    | NS      |
| Erythrocyte (T/L)    | 4.7±0.35     | 4.7±0.38    | NS      |
| Thrombocyte (G/L)    | 235±56       | 236±53      | NS      |
| Uric acid (mg/dL)    | 5.1±1.2      | 4.6±1.0     | 0.057   |
| Bilirubin (mg/dL)    | 0.56±0.3     | 0.62±0.29   | 0.02    |
| ALP (U/L)            | 65±18        | 62±17       | 0.04    |
| ASAT (U/L)           | 24±6         | 23±4        | NS      |
| ALAT (U/L)           | 27±10        | 27±8        | NS      |
| Gama GT (U/L)        | 29±19        | 27±15       | NS      |
| Creatine kinase (U/L)| 115±43       | 104±25      | NS      |
| CRP (mg/dL)†         | 0.38 (0.02–1.38) | 0.31 (0.02–1.15) | NS      |
| Total cholesterol (mg/dL) | 169±48   | 148±34      | 0.05    |
| LDL (mg/dL)          | 86±33        | 79±25       | NS      |
| HDL (mg/dL)          | 52±14        | 50±13       | NS      |
| Triglyceride (mg/dL) | 158±92       | 139±43      | NS      |

*Compared with values 3 months after receiving SGLT2i therapies.
†Data not normally distributed, log10 transferred for analysis and presented as mean (range).
ALAT, alanine aminotransferase; ALP, leukocyte phosphatase; ASAT, aspartate aminotransferase; CRP, C-reactive protein; Gamma GT, gamma-glutamyl transferase; HbA1c, glycated hemoglobin; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; NS, not significant; SGLT2i, sodium-glucose linked transporter-2 inhibitor; T2DM, type 2 diabetes mellitus.

Prediction of response to SGLT2i therapy

HbA1c levels decreased from 7.5% (58 mmol/mol)±0.9 at baseline to 6.9% (52 mmol/mol)±0.6 after 3 months of SGLT2i therapy (p<0.001). Out of 20 patients, 16 (80%) with T2DM showed documented treatment response, and 4 (20%) patients showed no change or increase in HbA1c levels and were rated as non-responder.

A significant negative correlation (r=−0.6, p=0.005) was found between the baseline HbA1c values and the reduction of HbA1c after 3 months of therapy. Moreover, non-responders had a significantly higher weight of 110±5 kg at baseline as compared with responders (82±12 kg, p<0.001).

Table 3  Measured non-imaging and imaging renal functional parameters in healthy subjects as well as in T2DM baseline and T2DM SGLT2i

| Renal parameters (mean±SD) | Healthy individuals | Patients with type 2 diabetes |
|---------------------------|---------------------|-----------------------------|
|                          | T2DM baseline       | T2DM SGLT2i                 | P value |
| Creatinine (mg/dL)       | 0.9±0.16            | 0.9±0.21                    | 0.95±0.23 | NS            |
| GFR (ml/min/1.73 m²)†    | 122±21*†            | 92±22*                      | 86±24†    | 0.001*†       |
| MTT (min)                | 4.3±1.8*            | 5.7±3.0*†                   | 4.4±2.2‡  | 0.012*, 0.004‡ |
| GRP                      | 5.1±1.1             | 4.7±1.0‡                    | 5.2±0.8‡  | 0.02‡         |

*Significant differences between healthy subjects and T2DM baseline.
†Significant differences between healthy subjects and T2DM SGLT2i.
‡Significant differences between T2DM baseline and T2DM SGLT2i.
GFR, glomerular filtration rate; GRP, general renal performance; MTT, mean transit time; NS, not significant; SGLT2i, sodium-glucose linked transporter-2 inhibitor; T2DM, type 2 diabetes mellitus.
Emerging Technologies, Pharmacology and Therapeutics

Figure 1

(A) Mean transit times of T2DMbaseline and T2DM SGLT2i versus healthy controls. Mean transit times at baseline were significantly higher than in healthy controls (5.7 min vs 4.3 min, p=0.012) and significantly higher than in 2 weeks after initiation of therapy (5.7 min vs 4.4 min, p=0.004). (B) GRP in T2DMbaseline and T2DM SGLT2i versus healthy controls. In comparison with healthy controls, T2DMbaseline revealed lower levels of GRP (5.1 min vs 4.7 min, p=0.06). Two weeks after SGLT2i treatment, GRP increased from 4.7 to 5.2 (p=0.02) and was almost equal to healthy volunteers. (C) GRP in T2DMbaseline and T2DM SGLT2i in relation to response to SGLT2i therapy. In case of responders to SGLT2i therapy, significant increase in GRP (p<0.01) was observed from baseline to 2 weeks after initiation of therapy (circles). No relevant changes (p=0.46) in GRP values among non-responder patients before and after initiation of to SGLT2i therapy were found (squares). GRP, general renal performance; SGLT2i, sodium-glucose linked transporter-2 inhibitor; T2DM, type 2 diabetes mellitus.

Regarding FDG parameters, although MTT at baseline and 2 weeks after initiation of therapy with SGLT2i was not significantly different between therapy responder and therapy non-responder patients with T2DM, GRP among responders was significantly higher after therapy as compared with baseline (5.3 vs 4.6, p<0.01). However, no linear correlation was found between HbA1c reduction and GRP increase in the responder group (r=−0.21). Also, no relevant changes in GRP values were observed among non-responder patients before and 3 months after initiation of therapy with SGLT2i (5.1 vs 5.0, p=0.47) (figure 1C).

Interestingly, levels of serum uric acid at baseline were inversely correlated with GRP in responders (r=−0.84, p<0.001), while there was no significant correlation found in non-responders (r=−0.58, p=0.42).

DISCUSSION

It is well known that kidneys play an important role in glucose homeostasis in both diabetic and non-diabetic conditions. SGLT2i therapies by preventing glucose input into the renal tubular cells protect kidneys from the deleterious effects of hyperglycemia among patients with T2DM.26

One of the main objectives of the current study was to investigate the effects of SGLT2i treatment on renal parameters in patients with T2DM receiving daily therapy for 2 weeks. In addition to routinely known standard renal parameters, dynamic FDG PET/MRI was used to provide in vivo renal function including SGLT2 transporter function, as FDG to a minor extent is used via SGLT2 and might therefore change its ordinary behavior in kidneys after obtaining SGLT2i. We primarily focused on the level of MTT, which is a surrogate marker to presage the kidney excretion rate, and on the level of kidney FDG uptake that represents FDG accumulation in renal parenchymal tissue and an important measure of GRP for kidney functionality.

As we compared FDG renal imaging parameters of the healthy subjects with that of patients with T2DM prior to receiving SGLT2i therapies, we found that the kidney tracer excretion rate in terms of MTT in healthy subjects was significantly lower than in T2DMbaseline, while FDG renal accumulation by means of GRP in the healthy cohort was significantly higher than of T2DMbaseline. Indeed, hyperglycemia impairs renal function, and therefore subjects with diabetes are at considerably higher risk of developing different degrees of renal diseases and have poorer renal function than individuals with no diabetes. About 40% of patients with diabetes will develop some degree of diabetic nephropathy in the course of the disease.27 Nevertheless, after only 2 weeks of SGLT2i therapies, the levels of MTT and GRP reached similar ranges as compared with healthy controls, which indicates FDG reactivity to SGLT2i. Reduction of FDG reabsorption under the influence of SGLT2i might induce availability of more FDG (1) for excretion, thus the
MTT of T2DM<sub>SGLT2</sub> is lower compared with T2DM<sub>baseline</sub>; and (2) for accumulation, thus GRP is higher in healthy controls and in T2DM<sub>SGLT2</sub> than in T2DM<sub>baseline</sub>. Accordingly, the results of the study showed that levels of MTT are lower and levels of GRP are higher in T2DM<sub>SGLT2</sub> than in T2DM<sub>baseline</sub>. Our observation of about 10% increase of GRP due to the inhibited FDG reabsorption is in good agreement with previous publications. 1

Moreover, among patients with diabetes, the results demonstrated, very interestingly, a significant decline in levels of MTT (ie, outflow or excretion efficacy) in T2DM<sub>SGLT2</sub> compared with T2DM<sub>baseline</sub>. Two weeks after initiation of therapy with gliflozins, GRP as a surrogate marker of kidney functionality increased significantly in T2DM<sub>SGLT2</sub> in comparison with T2DM<sub>baseline</sub>. Interestingly, among the responders to SGLT2i therapy, values of GRP were significantly higher after therapy as compared with baseline; thus, GRP only 2 weeks after the therapy was significantly higher than the baseline if HbAlc was reduced 3 months after initiation of therapy with SGLT2i.

We previously demonstrated the feasibility and validity of kidney functional parameters such as split function, MTT, GFR and effective renal plasma flow as determined with dynamic FDG PET/MRI. Likewise, with the help of high-resolution MRI sequences, we could exactly delineate morphological structures to monitor the FDG concentration over time. 13 Consequently, our study highlights and confirms the nephroprotective effects of SGLT2i therapies among patients with T2DM. Matching these results, in vivo and in vitro studies indicated that SGLT2i lowers glomerular hyperfiltration and diminishes tubulointerstitial inflammation and fibrosis that are induced by the elevated glucose in the tubular cells of patients with diabetes. 28 29

Regarding non-imaging renal parameters, although levels of serum creatinine did not differ significantly between the healthy cohort and the patients with T2DM, the results revealed that the studied patients with T2DM, 90% of whom suffered from high blood pressure at the same time (as shown in table 1), had a significantly lower GFR than healthy controls. Notably, levels of GFR among the cohort with diabetes further declined 2 weeks after starting SGLT2i therapies. This observation is compatible with the results of previous studies which revealed an early, short-term, and reversible reduction in GFR a few weeks after initiation of SGLT2i therapies that spontaneously reversed with the continuation of treatment. 10

Limitation of the study
Since the study was a proof of concept to show the impact of SGLT2i on the FDG renal function parameters, it did not include another comparator arm with other antidiabetic therapies. In addition, the small sample size of patients with T2DM recruited for this clinical trial may limit the results of this study. Hence, we currently lack the plausible reasons behind the relation of GRP to HbA1c observed among the participants and we strive to clarify it within the frame of our planned future studies.

CONCLUSIONS
SGLT2i therapies induced a significant improvement in kidney function of patients with T2DM as indicated by reduced MTT and improved GRP already 2 weeks after initiation of the therapy. Moreover, early increase of GRP was associated with long-term glycemic response to SGLT2i therapies.

REFERENCES
1 Sala-Rabanal M, Hirayama BA, Ghezzi C, et al. Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol 2016;594:4425–38.
2 Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733–94.
3 Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427–34.
4 Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 2012;14:94–6.
5 Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU); 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941–50.
6 Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010:33:2217–24.
Emerging Technologies, Pharmacology and Therapeutics

7 Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. *Diabetes Obes Metab* 2012;14:539–45.

8 Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. *Diabetes Care* 2012;35:1473–8.

9 Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2014;2:369–84.

10 Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab* 2013;15:463–73.

11 Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;380:2295–306.

12 Qiao H, Bai J, Chen Y, et al. Kidney modelling for FDG excretion with PET. *Int J Biomed Imaging* 2007;2007:63234.

13 Szabo Z, Xia J, Mathews WB, et al. Future direction of renal positron emission tomography. *Semin Nucl Med* 2006;36:36–50.

14 Kobayashi M, Shikano N, Nishi R, et al. Comparison of the transcellular transport of FDG and D-glucose by the kidney epithelial cell line, LLC-PK1. *Nucl Med Commun* 2010;31:141–6.

15 Geist BK, Baltzer P, Fueger B, et al. Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects. *EJNMMI Res* 2018;8:37.

16 Fleming JS, Kemp PM. A comparison of deconvolution and the Patlak-Rutland plot in renography analysis. *J Nucl Med* 1999;40:469–7.

17 Gates GF. Split renal function testing using Tc-99m DTPA. A rapid technique for determining differential glomerular filtration. *Clin Nucl Med* 1983;8:400–7.

18 American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2019;42:S90–102.

19 Wesolowski MJ, Conrad GR, Šámal M, et al. A simple method for determining split renal function from dynamic (99m)Tc-MAG3 scintigraphic data. *Eur J Nucl Med Mol Imaging* 2016;43:550–8.

20 Ortapamuk H, Naldoken S, Tekdogan UY, et al. Differential renal function in the prediction of recovery in adult obstructed kidneys after pyeloplasty. *Ann Nucl Med* 2003;17:663–8.

21 Gates GF. Glomerular filtration rate: estimation from fractional renal accumulation of 99mTc-DTPA (stannous). *AJR Am J Roentgenol* 1982;138:565–70.

22 Durand E, Blaufox MD, Britton KE, et al. International scientific Committee of radionuclides in Nephrology (ISCORN) consensus on renal transit time measurements. *Semin Nucl Med* 2008;38:82–102.

23 Kempi V. A FORTRAN program for deconvolution analysis using the matrix algorithm method with special reference to renography. *Comput Methods Programs Biomed* 1987;24:107–16.

24 Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. *Anal Chem* 1964;36:1627–39.

25 Fleming JS. Functional radionuclide imaging of renal mean transit time and glomerular filtration rate. *Nucl Med Commun* 1988;9:85–96.

26 Andrianesis V, Glykofridi S, Doupis J. The renal effects of SGLT2 inhibitors and a mini-review of the literature. *Ther Adv Endocrinol Metab* 2016;7:212–28.

27 American Diabetes Association. Standards of medical care in diabetes—2014. *Diabetes Care* 2014;37 Suppl 1:S14–80.

28 Vallon V, Gerasimova M, Rose MA, et al. Sglt2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. *Am J Physiol Renal Physiol* 2014;306:F194–204.

29 Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? *PloS One* 2013;8:e54442.

30 Kelly MS, Lewis J, Huntsberr AM, et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. *Postgrad Med* 2019;131:31–42.